Incompatible Crossmatch in a Patient with Sickle Cell Disease and Historical Antibodies
A 45-year-old woman with sickle cell disease (HbSS) is admitted with vaso-occlusive pain and a hemoglobin of 6.8 g/dL (68 g/L), reticulocytes 11%, and absolute neutrophil count 2.1×10^9/L. She has received 14 units of red cells over the past 8 years. Her record documents anti-E and anti-Jk^a; the current antibody screen is negative by gel, and the autocontrol is negative. Because of worsening pain and a hemoglobin that has fallen from 7.9 g/dL two weeks earlier, the team requests 2 units of red cells. The blood bank crossmatches two group O, D-negative units: unit 1 is compatible by immediate spin and AHG; unit 2 is compatible by immediate spin but 1+ incompatible at AHG. The patient's last transfusion was 19 days ago. No new alloantibody is identified on the current panel, and the referring team asks whether the incompatible unit can be given because the patient is symptomatic.
1. How should the blood bank resolve the incompatible crossmatch, and what is the most likely explanation? Include the role of the historical antibodies and the 19-day interval.
Read the worked answer
The incompatible AHG crossmatch with a negative antibody screen and negative autocontrol points to a low-titer alloantibody rather than a warm autoantibody. Kidd antibodies are notorious for evanescence and for causing delayed hemolytic transfusion reactions; the 19-day interval since transfusion is consistent with an anamnestic response. The historical record is key: a previously identified anti-Jk^a should be treated as clinically significant even when current screening is negative. I would repeat the antibody screen with a different method or enhancement (for example, polyethylene glycol or gel), test the incompatible unit's red cells against the patient's plasma, and review the current panel for Jk^a and E. If the unit is Jk^a-positive or E-positive, it should not be released. The blood bank should select units negative for E and Jk^a, ideally with extended phenotype matching, and crossmatch by AHG. If no compatible units can be found urgently, the transfusion service physician must be involved; giving the incompatible unit is a last resort because it may cause a delayed hemolytic transfusion reaction.
2. What red cell antigen-matching strategy is appropriate for this patient, and what should be done if she needs urgent transfusion before phenotyped units are available?
Read the worked answer
For sickle cell disease, extended red cell antigen matching should include C, c, E, e, and K, and often Jk^a/Jk^b, Fy^a/Fy^b, and S/s, to reduce alloimmunization. Because she has anti-E and anti-Jk^a, at minimum provide E-negative and Jk^a-negative units. If transfusion is urgent, group O D-negative units can be issued uncrossmatched only with physician approval; however, the blood bank should first screen inventory for E- and Jk^a-negative units, even if that means contacting another site. Phenotyping the patient now is unreliable because she was transfused 19 days ago; molecular typing or a pretransfusion sample may help, but historical phenotype takes precedence. Do not use the incompatible unit simply because the patient is symptomatic if antigen-negative units can be obtained.
3. What laboratory findings would support a delayed hemolytic transfusion reaction rather than a new alloimmunization, and how would you monitor the patient?
Read the worked answer
A delayed hemolytic transfusion reaction is supported by a falling hemoglobin despite transfusion, rising LDH and indirect bilirubin, low haptoglobin, and a positive DAT or eluate; the antibody screen may remain negative because the antibody is absorbed onto donor cells. New alloimmunization would typically show a new antibody on an extended panel, though it can also be evanescent. Monitor CBC, reticulocyte count, bilirubin, LDH, haptoglobin, and urine hemoglobin, and watch for pain crisis and renal injury. Report the event to the transfusion service and consider extended phenotyping or molecular typing for future transfusions.